Synthesis and Structure–Activity Relationship Studies of Derivatives of the Dual Aromatase–Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate

doi:10.1002/cmdc.201300015

Paper

Synthesis and Structure–Activity Relationship Studies of Derivatives of the Dual Aromatase–Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate

Published Mar 11, 2013 · L. Woo, P. Wood, C. Bubert

Chemmedchem

Q1 SJR score

28

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

4‐{[(4‐Cyanophenyl)(4H‐1,2,4‐triazol‐4‐yl)amino]methyl}phenyl sulfamate and its ortho‐halogenated (F, Cl, Br) derivatives are first‐generation dual aromatase and sulfatase inhibitors (DASIs). Structure–activity relationship studies were performed on these compounds, and various modifications were made to their structures involving relocation of the halogen atom, introduction of more halogen atoms, replacement of the halogen with another group, replacement of the methylene linker with a difluoromethylene linker, replacement of the para‐cyanophenyl ring with other ring structures, and replacement of the triazolyl group with an imidazolyl group. The most potent in vitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG‐3 cell preparation of 0.2 and 2.5 nM, respectively. The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028 nM in the same assay.

Study Snapshot

The imidazole derivative of 4-[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl-phenyl sulfamate] is the most potent in vitro dual aromatase and s

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Synthesis and Structure–Activity Relationship Studies of Derivatives of the Dual Aromatase–Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate

Sign up to use Study Snapshot

References

Novel aromatase inhibitors by structure-guided design.

Structure-guided design of novel aromatase inhibitors reveals potential for next-generation treatments for estrogen-dependent breast cancer.

Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors.

The most potent steroid sulfatase inhibitor synthesized is 4-nitroEMATE, with halogens preferred at the 2-position and nitro at the 4-position.

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates

The S-(+)-enantiomer of 2bromo-4(2(4-cyanophenyl)2(1H1,2,4triazol1yl)ethyl)phenyl sulfamate is the most potent

Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity.

Hybrid dual aromatase-steroid sulfatase inhibitors show improved potency and potential for multitargeted treatment of hormone-dependent breast cancer.

Bicyclic Derivatives of the Potent Dual Aromatase–Steroid Sulfatase Inhibitor 2‐Bromo‐4‐{[(4‐cyanophenyl)(4H‐1,2,4‐triazol‐4‐yl)amino]methyl}phenylsulfamate: Synthesis, SAR, Crystal Structure, and in vitro and in vivo Activities

Bicyclic ring-containing dual aromatase-sulfatase inhibitors show potent inhibition of aromatase and steroid sulfatase, offering a potential new treatment option for hormone-dependent breast cancer.

Citations

De novo cholesterol biosynthesis: an additional therapeutic target for the treatment of postmenopausal breast cancer with excessive adipose tissue

Statins and metformin inhibit de novo cholesterol synthesis, potentially improving the prognosis of postmenopausal breast cancer patients with excessive adipose tissue and triple-negative breast cancer.

Dual Targeting of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 by a Novel Drug-Prodrug Approach: A Potential Therapeutic Option for the Treatment of Endometriosis.

A novel drug-prodrug approach successfully creates promising compounds for treating endometriosis and other estrogen-dependent diseases by targeting steroid sulfatase and 17-hydroxysteroid dehydrogenase type 1.

Polypharmacology: The Science of Multi-targeting Molecules.

Polypharmacology, where a molecule can interact with multiple targets simultaneously, offers advantages in complex diseases like cancer, making it more effective than single-targeting drugs.

Steroid Sulphatase and Its Inhibitors: Past, Present, and Future

Steroid sulphatase inhibitors show potential as therapeutic agents in hormone-dependent cancers and non-oncological conditions, with Irosustat being the only one to complete clinical trials.

On the hydrolysis of diethyl 2-(perfluorophenyl)malonate

This study presents a new method for synthesizing 2-(perfluorophenyl)acetic acid without handling toxic substances, offering a 63% preparative yield and avoiding toxic substances like cyanides and perfluorinated benzyl halides.

Aromatase inhibitors: Role in postmenopausal breast cancer.

Aromatase inhibitors play a crucial role in postmenopausal breast cancer treatment, but new, safer drugs are needed for better safety and efficacy.

Recent Studies on Aromatase and Sulfatase Involved in Breast Cancer and their Inhibitors

Aromatase inhibitors and sulfatase inhibitors are key therapeutic targets in breast cancer, with potential for dual inhibitors to overcome acquired resistance.

Unexpected outcome of the Zn(OTf)2-catalyzed arylhydrazination of alkanoyl propargylamines: Rapid entry into 1-(arylamino)imidazoles

The Zn(OTf)2-catalyzed arylhydrazination of alkanoyl propargylamines leads to N-anilinoimidazoles, an unexpected reaction outcome due to the high electrophilicity of the alkanoic carboxamide carbon atom.